Investigational drug · Phase 2
HRZE
Also called: Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Tuberculoses, Tuberculosis Meningitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
30
Any phase or sponsor naming "HRZE"
First trial start
2025
Oct 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRZE", any sponsor or status.
- Phase 224
Conditions studied
As listed on its trial records.
- Pulmonary Tuberculoses
- Tuberculosis Meningitis
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "HRZE" as an intervention, largest first.
- Optimizing Antituberculosis Therapy in Adults With Tuberculous MeningitisPivotal-lookingStatus unknown
Beijing Chest HospitalAcademic, hospital or other
NCT03787940 · 676 participants (planned) · Start Mar 4, 2019 · Primary completion Dec 31, 2021
Drug: Isoniazid · For: Tuberculous Meningitis
Sites: Beijing, China; Jiamusi, China; Nanchang, China · 4 sites in all
- Efficacy of HUEXC030 in Subjects With Pulmonary TuberculosisPivotal-lookingCompleted
Orient Pharma Co., Ltd.Industry
NCT02467608 · 557 participants · Start Dec 6, 2012 · Primary completion Jan 9, 2019
Drug: Isoniazid with HUEXC030 and RZE; HRZE · For: Pulmonary Tuberculosis
Sites: Changhua, Taiwan; Chiayi City, Taiwan; Kaohsiung City, Taiwan · 18 sites in all
- Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis PatientsCompleted
Tuberculosis Research Centre, IndiaGovernment (non-federal)
NCT05047055 · 550 participants · Start Mar 15, 2022 · Primary completion Apr 17, 2026
Drug: Isoniazid; Rifampicin and 3 more · For: Tuberculosis, Pulmonary
Sites: Chennai, India
- Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult PatientsPivotal-lookingCompleted
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
NCT03338621 · 455 participants · Start Jul 30, 2018 · Primary completion Jul 1, 2021
Drug: Pretomanid; Bedaquiline and 4 more · For: Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR and 2 more
Sites: Rio de Janeiro, Brazil; Tbilisi, Georgia; Kuala Lumpur, Malaysia · 26 sites in all
- TBTC Study 28: Moxifloxacin Versus Isoniazid for TB TreatmentPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00144417 · 433 participants · Start Feb 2006 · Primary completion Jun 2007
Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol); isoniazid · For: Tuberculosis
Sites: Little Rock, Arkansas; Los Angeles, California; San Diego, California · 26 sites in all
- Intensified Short Course Regimen for TBM in AdultsPivotal-lookingNot yet recruiting
Indian Council of Medical ResearchGovernment (non-federal)
NCT05917340 · 372 participants (planned) · Start Mar 2024 · Primary completion Sep 2027
Drug: High dose rifampicin (25mg/kg); Moxifloxacin 400mg and 7 more · For: Tuberculous Meningitis
Sites: Chennai, India
- Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS DesignPivotal-lookingCompleted
Michael HoelscherAcademic, hospital or other
NCT01785186 · 365 participants · Start Apr 2013 · Primary completion Sep 2014
Drug: SQ109; Rifampicin and 4 more · For: Tuberculosis, Pulmonary
Sites: Bellville, South Africa; Cape Town, South Africa; Johannesburg, South Africa · 7 sites in all
- A Pan-TB Regimen Targeting Host and MicrobePivotal-lookingActive, not recruiting
The Aurum Institute NPCAcademic, hospital or other
NCT05686356 · 352 participants (planned) · Start Jul 28, 2023 · Primary completion Jan 2026
Drug: Sutezolid; N-acetyl cysteine and 2 more · For: Tuberculosis
Sites: Maputo, Mozambique; Durban, South Africa; Johannesburg, South Africa · 8 sites in all
- Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary TuberculosisPivotal-lookingActive, not recruiting
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
NCT06058299 · 309 participants · Start Oct 31, 2023 · Primary completion Dec 27, 2024
Drug: sorfequiline; Pretomanid and 4 more · For: Pulmonary TB; Pulmonary Tuberculosis; Drug Sensitive Tuberculosis
Sites: Tbilisi, Georgia; Dasmariñas, Philippines; Makati City, Philippines · 22 sites in all
- Short-course Regimens for the Treatment of Pulmonary TuberculosisPivotal-lookingActive, not recruiting
Centers for Disease Control and PreventionFederal agency
NCT05766267 · 288 participants (planned) · Start Nov 21, 2023 · Primary completion Dec 31, 2026
Drug: Rifabutin; Delamanid and 6 more · For: Tuberculosis, Pulmonary; Tuberculosis Infection
Sites: Seattle, Washington; Montreal, Canada; Vancouver, Canada · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Adverse drug reactions among children with tuberculosis in China: a multicentre study, 2017-2022.
Zhou Y, Kan Y, Liu P, et al. · Ann Med 2026
- Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against Mycobacterium tuberculosis in an NHP model evaluated by [18F] FDG PET/CT and bacterial burden.
Via LE, Sarathy J, Weiner DM, et al. · Antimicrob Agents Chemother 2026
- Individualized TB care for drug-susceptible pulmonary tuberculosis: clinical alternatives when HRZE is contraindicated or not tolerated.
Allavena L, Mencarini J, Fumagalli G, et al. · Expert Rev Respir Med 2026
- Computational toxicology analysis of candidate drivers and pathways in HRZE-associated drug-induced liver injury.
Lai Y, Yang X, Tian H, et al. · Toxicol Mech Methods 2026
- Clinical efficacy, safety evaluation, and mechanism of acetylcysteine in improving first-line anti-tuberculosis treatment of newly diagnosed pulmonary TB: an open-label, randomized, single-center trial.
Zhang H, Liu M, Shi L, et al. · Front Med (Lausanne) 2026
- Rare isolated basal vein of Rosenthal thrombosis causing thalamic haemorrhage during intensive-phase antituberculous therapy: a case report.
Walikonthage BN, Udurawana AMJB, Kumarihamy P, et al. · J Med Case Rep 2026
Also in development for Pulmonary Tuberculoses
- RESP30TBPhase 21 trial
Thirty Respiratory Limited · Pulmonary Tuberculoses
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.